Other
Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
100%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 3
2(100.0%)
2Total
Phase 3(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT00039780Phase 3Completed
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Role: collaborator
NCT00966914Phase 3Completed
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
Role: collaborator
All 2 trials loaded